{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Allurion Technologies, Inc.
Allurion Technologies Hits 52-Week Low at $1.30 Amid Financial Struggles
Allurion Technologies, Inc. has reached a new 52-week low, experiencing a significant decline in stock price over the past year. The company, with a market capitalization of approximately USD 17 million, faces financial challenges, including negative book value and losses, raising concerns about its long-term viability.
Allurion Technologies Hits 52-Week Low at $1.35 Amid Financial Struggles
Allurion Technologies, Inc. has reached a new 52-week low, reflecting a substantial decline in its stock price over the past year. The company, with a market capitalization of approximately USD 17 million, reported net sales of USD 3.38 million and faces challenges including rising raw material costs and a negative book value.
Allurion Technologies Hits 52-Week Low at $1.80 Amidst Major Decline
Allurion Technologies, Inc. has reached a new 52-week low, experiencing a substantial decline in stock price over the past year. The company, with a market capitalization of approximately USD 17 million, is facing financial difficulties, including negative book value and losses, raising concerns about its long-term viability.
Allurion Technologies Hits New 52-Week Low at $1.84 Amid Declining Sales
Allurion Technologies, Inc. has reached a new 52-week low, experiencing a significant decline in stock price over the past year. The company, with a market capitalization of approximately USD 17 million, reported low net sales and a negative book value, indicating challenges in financial stability and long-term viability.
Allurion Technologies Hits 52-Week Low at $1.89 Amidst Major Decline
Allurion Technologies, Inc. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company, with a market capitalization of approximately USD 17 million, faces challenges including a negative book value and weak debt servicing ability, despite showing some operational efficiency.
Is Allurion Technologies, Inc. technically bullish or bearish?
As of August 25, 2025, Allurion Technologies, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 significantly with a year-to-date return of -80.93%.
Is Allurion Technologies, Inc. overvalued or undervalued?
As of August 9, 2023, Allurion Technologies, Inc. is considered risky and overvalued, with a negative Price to Book Value of -0.29, a P/E ratio of -0.4984, and a year-to-date stock performance decline of 77.58%, significantly underperforming the S&P 500's 2.44% return.
Is Allurion Technologies, Inc. technically bullish or bearish?
As of May 14, 2025, the market trend is mildly bearish, indicated by daily moving averages showing bearish momentum, while weekly MACD and KST suggest mild bullishness, resulting in mixed signals overall.
What does Allurion Technologies, Inc. do?
Allurion Technologies, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $6 million and a net profit of $7 million as of March 2025. Key metrics include a market cap of $19.02 million, a return on equity of 54.67%, and no dividend yield.
How big is Allurion Technologies, Inc.?
As of Jun 18, Allurion Technologies, Inc. has a market capitalization of 19.02 million and reported net sales of 28.31 million, with a net profit of -24.35 million. The balance sheet shows shareholder's funds at -77.98 million and total assets of 32.81 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
